Saif Ahmad
Dr. Saif Ahmad is a British-Pakistani academic oncologist, cancer researcher, and entrepreneur who co-founded 52 North Health alongside his partner Umaima Ahmad in 2018. He holds an MD-PhD and brings over 15 years of experience in cancer medicine, having trained and practiced as a Consultant Clinical Oncologist at Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust. His research is affiliated with the CRUK Cambridge Centre, and he holds an Assistant Professorship at the University of Cambridge's Department of Oncology. He is also an NHS Clinical Entrepreneur and an Innovation Fellow of the Canada-UK Foundation, with peer-reviewed publications that have been covered in The New York Times, BBC News, and the British Medical Journal.
The idea for 52 North Health originated from a conversation Saif had with Umaima while she was completing her MPhil in Bioscience Enterprise at Cambridge in 2017. When she asked him to identify the most pressing unmet clinical problems he encountered, he described neutropenic sepsis — the life-threatening immune system collapse that chemotherapy causes and which kills three people in England and Wales every day. He became the company's Chief Scientific and Medical Officer, bringing his deep clinical knowledge of oncology, the realities of chemotherapy treatment pathways, and the evidence base for diagnostic decision-making directly into the product development process. His clinical grounding has been central to ensuring NeutroCheck® is designed around real patient and clinician needs.
As CSMO, Saif has led 52 North's scientific and clinical strategy, co-authoring publications, presenting at international conferences, and engaging with strategic advisors at AstraZeneca and NHSx. He also serves as an Assistant Editor on the Royal College of Radiologists' Clinical Oncology Journal. Under his scientific leadership, 52 North has secured funding from Cancer Research Horizons, Cedars-Sinai Health Ventures, KHP Ventures, and the Defence Innovation Accelerator for the North Atlantic (NATO DIANA), and has obtained Innovative Device Access Pathway (IDAP) breakthrough status from the UK Government — one of the most significant regulatory fast-track designations available to British medtech companies.
